While inhibiting T-reg immunosuppressive functions in tumors might be essential to enhance anti-cancer immunotherapy, most of the functional studies regarding IGF1/IGF1R axis have been performed to boost the function of T-reg activity in the treatment of autoimmune diseases such as type-I diabetes, dermatitis and multiple sclerosis (50). This evidence concerns the gene IGF1 and cancer.